China Pharma 

$0.6400
53
-$0.05-6.61% Wednesday 19:59
+$0.00+0%Wednesday 20:10After hours

Statistics

Day High
0.7344
Day Low
0.64
52W High
2.03
52W Low
0.38
Volume
49,454
Avg. Volume
286,756
Mkt Cap
3.21M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

18MayExpected
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
-0.2
-0.13
-0.07
0
Expected EPS
0
Actual EPS
-0.1988

Financials

-104.57%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
9.06MRevenue
-9.47MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CPHI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
Show more...
CEO
Ms. Zhilin Li
Employees
224
Country
United States
ISIN
US16941T4013

Listings

0 Comments

Share your thoughts

FAQ

What is China Pharma stock price today?
The current price of CPHI is $0.64 USD — it has decreased by -6.61% in the past 24 hours. Watch China Pharma stock price performance more closely on the chart.
What is China Pharma stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange China Pharma stocks are traded under the ticker CPHI.
Is China Pharma stock price growing?
CPHI stock has fallen by -17% compared to the previous week, the month change is a -15.76% fall, over the last year China Pharma has showed a -58.71% decrease.
What is China Pharma market cap?
Today China Pharma has the market capitalization of 3.21M
What were China Pharma earnings last quarter?
CPHI earnings for the last quarter are -0.2 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is China Pharma revenue for the last year?
China Pharma revenue for the last year amounts to 9.06M USD.
What is China Pharma net income for the last year?
CPHI net income for the last year is -9.47M USD.
How many employees does China Pharma have?
As of June 25, 2026, the company has 224 employees.
In which sector is China Pharma located?
China Pharma operates in the Health & Wellness sector.
When did China Pharma complete a stock split?
The last stock split for China Pharma was on April 15, 2025 with a ratio of 1:10.
Where is China Pharma headquartered?
China Pharma is headquartered in Haikou, United States.